We presented a general overview of therapeutic strategies against DOT1L for MLL-rearranged leukemias, including DOT1L enzymatic inhibitors, DOT1L degraders, PPI inhibitors, and combinatorial interventions. The gene discussed is DOT1L; the disease is leukemia.